Sign in
Taking people in United StatesNo phase

Collects tissue and fluid samples from people with cancer for research

Collects tissue and fluid samples from people with cancer, lymphoma, myeloma or myelodysplastic syndrome.

Key facts

Who runs it
National Cancer Institute (NCI)
Where
Ann Arbor, Atlanta, Aurora, Baltimore, Bethesda, Buffalo, Charleston, Charlottesville, Columbus, Indianapolis, Iowa City, Pittsburgh, Sacramento, Salt Lake City, Seattle, and St Louis, United StatesSee the 16 sitesAlso in 1 other country, 1 site
Trial code
Registry title
Collection of Tissue Samples for Cancer Research
Status
Recruiting
People taking part
5,000 people, planned
Started
6 Jul 2006
Type of study
Observational, 4 groups
Treatments tested
  • Biopsy
Record updated
27 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults and children with cancer who are being evaluated or treated at the NIH Clinical Center or partner sites. Samples are collected for cancer research.

Age
Adults 18 years and older, and children older than 2 months and younger than 18 years.
Sex
All sexes can join.
Disease stage
Adults: newly diagnosed cancer not yet treated, cancer that came back or is growing during treatment, or treatment under way with response not yet checked. Ongoing partial response or stable disease can also join. Children: confirmed cancer (solid tumor or blood cancer) already having a needed medical procedure.
Earlier treatment
Adults can be untreated, previously treated, or in treatment. Infection medicines must be finished at least 1 week (7 days) before sample collection.

Main reasons for not taking part

  • HIV, active or chronic hepatitis B or C, or hepatitis A
  • Invasive fungal infection, or an active or uncontrolled infection
  • Benign tumors, carcinoma in situ, or complete response
  • Cancer-like conditions such as systemic mastocytosis, Langerhans cell histiocytosis or MGUS (adults)
  • Blood-only collection when disease shows ongoing partial response or stable disease

The registry criteria, word for word

Show all 22 criteriaShow less

Who can take part

  • Patients younger than 18 years of age and older than 2 months with a histologically or cytologically confirmed diagnosis of cancer (solid tumor or hematologic malignancy) who are being treated for cancer at the NIH Clinical Center or participating clinical sites and who will already be undergoing a clinically necessary medical procedure during which tumor tissue will be resected or needle biopsy tissue or bone marrow aspirate collected. Tissue from neonates will not be collected
  • Ability and willingness to assent to participation, utilizing an explanation that is understandable/age appropriate, as well as receiving parental permission; At the NIH Clinical Center ONLY; -At the PI s discretion, clinically indicated tissue collections may occur from patients with pediatric tumors that are generally benign but are known to undergo malignant transformation, e.g., neurofibromatosis, osteochondromas, pheochromocytoma, etc

Who cannot take part

  • Patients with active and/or uncontrolled infections or who are still recovering from an infection:; All antibiotics, antifungals, or antivirals prescribed for the treatment of an infection should be completed at least 1 week (7 days) prior to collection; No recurrence of fever or other symptoms related to infection for at least 1 week (7 days) following completion of antibiotics; Patients receiving antibiotics, antifungals, or antivirals for prophylaxis are permissible; Antibiotics being administered topically at a location distant from the planned tissue collection site or eye drops for a localized infection are permissible; Note: Use of antibiotics for prophylaxis is not an exclusion
  • Patients with active and/or uncontrolled infections or who are still recovering from an infection:; Actively febrile patients with uncertain etiology of febrile episode; All antibiotics should be completed at least 1 week (7 days) prior to collection; No recurrence of fever or other symptoms related to infection for at least 1 week (7 days) following completion of antibiotics; Note: Use of antibiotics for prophylaxis is not an exclusion
  • Note: Testing for bloodborne pathogens or other infections is not required for eligibility assessment and will be performed only if clinically indicated. Exclusion criteria for bloodborne pathogens and/or other infections is based on existing documentation in the medical record or patient report of such diagnosis at the time of eligibility assessment, if testing is not obtained for clinical indications
  • Patients with cancer-like syndromes and/or blood disorders such as but not limited to systemic mastocytosis, Langerhans cell histiocytosis, chronic eosinophilic leukemia/hypereosinophilic syndrome, lymphomatoid granulomatosis, or monoclonal gammopathy of undetermined significance (MGUS)
  • Patients with invasive fungal infections
  • Patients with Human Immunodeficiency Virus (HIV), active or chronic hepatitis (i.e., quantifiable HBV-DNA and/or positive HbsAg, quantifiable HCV-RNA) or known history of HCV or HBV
  • Patients with Hepatitis A as indicated by anti-HAV IgM reactivity; --Note: Patients that are anti-HAV IgG reactive only are not excluded
  • Blood only collections from patients with solid tumors or hematologic malignancy demonstrating partial or stable disease response:; Blood will not be collected from patients whose disease demonstrates ongoing partial response or ongoing stable disease given the poor rate of model generation from such specimens; Blood will not be collected from patients between doses within a single treatment cycle
  • Specimen collections from patients with benign tumors including but not limited to desmoid tumors, carcinoma in situ, or ongoing evidence of complete disease response (CR)
  • Note: Testing for bloodborne pathogens or other infections is not required for eligibility assessment and will be performed only if clinically indicated. Exclusion criteria for bloodborne pathogens and/or other infections is based on existing documentation in the medical record or patient report of diagnosis at the time of eligibility assessment, if testing is not obtained for clinical indications
  • Patients with invasive fungal infections
  • Patients with Human Immunodeficiency Virus (HIV), active or chronic hepatitis (i.e., quantifiable HBV-DNA and/or positive HbsAg, quantifiable HCV-RNA) or known history of HCV or HBV
  • Patients with Hepatitis A as indicated by anti-HAV IgM reactivity; --Note: Patients that are anti-HAV IgG reactive only are not excluded
  • Specimen collections from patients with benign tumors including but not limited to desmoid tumors, carcinoma in situ, or ongoing evidence of complete disease response (CR) based on imaging
  • Blood only collections from patients with partial or stable disease response:; Blood will not be collected from patients whose disease demonstrates ongoing partial response or ongoing stable disease given the poor rate of model generation from such specimens; Blood will not be collected from patients between doses within a single treatment cycle

Other criteria

  • INCLUSION CRITERIA - ADULT:
  • Patients 18 years of age and older who are being evaluated and/or treated for cancer at the NIH Clinical Center or at participating sites:; Who have a newly diagnosed malignancy for which they have not yet received treatment, or; Who have a previously treated malignancy that is now recurrent or currently progressing on treatment indicated by:; radiographic evidence of tumor growth and/or new metastases, or; CBC w/differential and/or flow cytometry, or; documented evidence by the treating physician of signs/symptoms of clinical disease progression, or; Who are currently undergoing treatment and for whom disease response has not yet been assessed,; ---In this circumstance, specimen collection should occur as distant in time from the most recent drug administration as possible such as after completion of a treatment cycle and immediately prior to initiation of the next cycle; Patients with ongoing partial response (PR) or stable disease (SD) are eligible; For solid tumor diagnoses, confirmation of viable malignancy and/or <90% tumor necrosis, fibrosis, or hemorrhage per the final pathology must be reported to the coordinating site for patients enrolled with ongoing PR or SD at the time of specimen collection; For hematologic malignancies, confirmation of viable malignancy must be reported to the coordinating site per the final flow cytometry report
  • Ability to understand and willingness to sign a written informed consent document indicating their willingness to have their tissue or biologic fluid specimens used for research as outlined in this protocol; At the NIH Clinical Center ONLY:
  • At the PIs discretion, specimens may be collected from patients 18 years of age and older prior to the development of an invasive cancer, who are being evaluated and/or treated for a confirmed familial cancer syndrome such as but not limited to Hereditary Breast and Ovarian Cancer (HBOC), Hereditary Non-polyposis Colorectal Cancer Syndrome or Hereditary Diffuse Gastric Cancer (HDGC) syndrome
  • Specimens, including blood only, can be collected from patients 18 years of age and older who are being evaluated and/or treated for a hematologic malignancy, including Myelodysplastic Syndrome (MDS) and/or MDS Myeloproliferative Neoplasm (MDS-MPN), that meet all other adult eligibility criteria; Due to the different characteristics of hematologic malignancies versus solid tumor malignancies, including methodology for assessment of disease response, residual disease, and progression, evaluation of these factors for determination of protocol eligibility should be made utilizing established standards such as hematopathology, flow cytometry, immunohistochemical analysis, etc

Where in United States

Also in 1 other country, 1 site

  • University of Michigan, Ann ArborAnn Arbor, United StatesContact: Nancy A Moore, R.N.No longer taking part
  • Emory UniversityAtlanta, United StatesContact: Kathryn S Sutton, MDTaking people
  • University of Colorado DenverAurora, United StatesContact: Nancy A Moore, R.N.No longer taking part
  • Johns Hopkins UniversityBaltimore, United StatesContact: Nyall London, M.D. PHDTaking people
  • National Institutes of Health Clinical CenterBethesda, United StatesContact: Nancy A Moore, R.N.Taking people
  • Roswell Park Cancer InstituteBuffalo, United StatesContact: John Kane, MDTaking people
  • Medical University of South CarolinaCharleston, United StatesContact: Nancy A Moore, R.N.No longer taking part
  • University of Virginia, CharlottesvilleCharlottesville, United StatesContact: Nancy A Moore, R.N.No longer taking part
  • Ohio State UniversityColumbus, United StatesContact: Jim Rocco, MD, PhDTaking people
  • Indiana University - PurdueIndianapolis, United StatesContact: Anna Maria Storniolo, MDTaking people
  • University of IowaIowa City, United StatesContact: Stephanie Chen, MDTaking people
  • University of Pittsburgh Medical CenterPittsburgh, United StatesContact: Rakesh Sindhi, MDTaking people
  • UC DavisSacramento, United StatesContact: Nancy A Moore, R.N.No longer taking part
  • University of UtahSalt Lake City, United StatesContact: Nancy A Moore, R.N.No longer taking part
  • Fred HutchinsonSeattle, United StatesContact: Kelly Smith, MD PhDTaking people
  • Washington University St. LouisSt Louis, United StatesContact: Roheena Panni, MDTaking people

About the trial

What the trial wants to find out

Background:

Read full original descriptionShow less

-Patients who are being evaluated and/or treated at the NIH Clinical Center and adult patients at participating sites will be entered onto this tissue procurement protocol for collection of tissue specimens.

Objectives:

* To obtain samples from adult and pediatric patients for research purposes from tests and procedures that are done as required by the primary research protocol(s) to which a patient is enrolled or as part of their standard-of-care treatment. * To obtain samples for research purposes from non-surgical procedures, such as percutaneous biopsies, performed for the sole purpose of obtaining tissue specimens or biological fluids for this protocol.

Eligibility:

-Adult patients (18 years of age and older) and pediatric patients (younger than 18 years of age) who are being evaluated for and/or treated for cancer at the NIH Clinical Center participating sites.

Design:

* This is a multicenter tissue procurement protocol with NCI as the coordinating center. * For adult patients: specimens for research purposes, as outlined in this protocol, will be obtained from tests and procedures that are done as required by the primary research protocols to which a patient is enrolled or as part of their standard-of-care treatment. Non-surgical procedures, such as percutaneous biopsies, may also be performed for the sole purpose of obtaining tissue specimens or biological fluids for this protocol. Tissues and biological fluids to be procured may include but are not limited to blood, serum, urine, tumor tissue, normal tissue, pleural fluid, CSF, saliva, bronchial alveolar lavage (BAL), circulating tumor cells, hair follicles, and bone marrow. These specimens will be stored with unique identifiers and used to perform only those research studies that are outlined in this protocol. * For pediatric patients: tumor biopsy/resection tissue used for pediatric preclinical model development will only be from tissue already being obtained as part of a procedure necessary for the patient s clinical care or as part of a primary research protocol; blood specimens will be collected as part of a blood collection already scheduled for the patient s clinical care or as part of the planned pre-procedure bloodwork; volumes collected will not exceed institutional research limits. * Given the risks associated with any invasive procedure, such as tumor biopsy, the procedure will be discussed in detail with the patients and their parents/guardian (as indicated), including the side effects, prior to obtaining a separate consent for each procedure. A separate consent will not be signed prior to obtaining samples by minimally invasive measures, such as venipuncture. * This study has two separate consent forms at the NIH Clinical Center: one for adult patients to donate specimens for ongoing research on assay development and studies of molecular pathways, and one for adult and age-appropriate pediatric patients to donate samples for the generation of preclinical models. The study also has consent form templates for adult and pediatric patients at participating sites to donate specimens to create preclinical models. * Patients may remain on study for the duration of their consent or completion of the planned procedure, whichever comes first.

The 4 groups in the trial

  • 1/Standard

    Standard

    Treatment: Biopsy

  • 2/Standard and Preclinical Models

    Standard and Preclinical Models

  • 3/Preclinical Models

    Preclinical Models

  • 4/Preclinical Models, Pediatric

    Preclinical Models, Pediatric

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Tissue Procurement Protocol for the Developmental Therapeutics Clinic, National Cancer Institute (NCI)
Plain-language title
Collects tissue and fluid samples from people with cancer for researchGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
27 October 2026